ON
ONCO.US Onconetix Inc
- Market cap
- USD 2.15M
- P/E
- 0.0x
- P/B
- 0.16x
- ROE
- -
- Dividend yield
- 19.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ONCO.US undervalued?
Graham numberThe Graham number of Onconetix Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Onconetix Inc fundamental analysis
No fundamental analysis for Onconetix Inc yet.
Onconetix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commerci…
Full company profileOnconetix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Onconetix Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 58.5K | 2.52M | 815K | 189K |
| Gross Profit | -573.00 | -3.06K | -4.89K | -6.75K | -1.13M | 1.06M | 633K | 108K |
| Operating Income | -880K | -1.62M | -3.42M | -13.5M | -36.0M | -56.5M | -6.34M | -8.31M |
| EBITDA | -821K | -1.60M | -3.41M | -13.4M | -36.7M | -57.6M | -13.3M | -11.3M |
| Net Income | -822K | -1.60M | -3.42M | -13.4M | -37.4M | -58.7M | -14.0M | -51.6M |
| EPS | -723 | -1,407 | -3,006 | -10,625 | -21,243 | -5,192 | -43 | -124 |
| Balance Sheet | ||||||||
| Total Assets | 6.08M | 4.81M | 3.08M | 26.3M | 87.5M | 28.2M | 24.9M | 15.5M |
| Total Liabilities | 82.6K | 78.3K | 1.64M | 3.92M | 86.1M | 18.6M | 9.16M | 4.04M |
| Shareholders' Equity | 6.00M | 4.73M | 1.45M | 22.4M | -5.60M | 9.61M | 15.8M | -17.3M |
| Cash & Short-term Investments | 6.05M | 4.31M | 1.93M | 25.8M | 4.55M | 647K | 5.22M | 2.74M |
| Total Debt | - | - | - | - | 9.89M | 9.45M | 48.8K | 105K |
| Cash Flow | ||||||||
| Operating Cash Flow | -825K | -1.73M | -2.04M | -8.68M | -13.6M | -10.5M | -9.68M | - |
| Capital Expenditure | 4.50K | 11.8K | 1.92K | 9.34K | 55.0K | 28.5K | 0.00 | 0.00 |
| Free Cash Flow | -830K | -1.74M | -2.05M | -8.68M | -13.6M | -10.5M | -9.68M | - |
| Ratios | ||||||||
| ROE | -13.7% | -33.8% | -236.2% | -59.9% | - | -610.7% | -89.0% | - |
| ROA | -13.5% | -33.2% | -110.8% | -51.0% | -42.7% | -208.3% | -56.3% | -332.0% |
| Net Profit Margin | - | - | - | - | -63,986.5% | -2,325.2% | -1,721.0% | -27,364.5% |
| Debt to Equity | - | - | - | - | - | 0.98x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Onconetix Inc dividends
- Dividend yield
- 19.04%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 410K | 1.25 | - |
| 2024 | USD 206K | 18 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 6, 2026.
Who owns Onconetix Inc
- Insiders 0.20%
- Institutions 7.59%
- Public & others 92.21%
- Shares outstanding 670K
- Free float 395K
Top funds holding ONCO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 22.6K | 0.38% | 0.00% | Sep 2026 |
Top institutions holding ONCO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 51.4K | 0.98% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 13.5K | 0.26% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 252.00 | 0.00% | +2,000.00% | Jun 2026 |
| Tower Research Capital LLC | 145.00 | 0.00% | 0.00% | Jun 2026 |
| Hollencrest Securities, LLC | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 21.00 | 0.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Onconetix Inc company profile
- Company name
- Onconetix Inc
- Ticker
- ONCO.US
- Exchange
- USA Stocks
- Listed since
- Feb 18, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 201 East Fifth Street, Cincinnati, OH, United States, 45202
- Phone
- 513 620 4101
- Website
- onconetix.com
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix Inc management
6- Ms. Karina M. FedaszInterim Chief Financial Officer · born 1973
- Mr. David Allan White C.A., C.P.A., ICD.DChief Executive Officer · born 1953
- Mr. Andrew D. Skibo Ph.D.Global Head of Biologics Operations
- Mr. Theodore Scott YohoHead of Business Development
- Dr. Ali I. Fattom Ph.D.Head of Science & Discovery
- Dr. Jay Newmark M.B.A., M.D.Chief Medical Officer